MiniMed to announce financial results for its fourth quarter and full fiscal year 2026

**MiniMed to Announce Q4 and Fiscal Year 2026 Financial Results**

NORTHRIDGE, Calif., April 13, 2026 — MiniMed (Nasdaq: MMED), a leading provider in diabetes technology, is set to disclose its financial results for the fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026. Early risers can access the news release at approximately 3:45 a.m. Pacific Daylight Time (PDT) by visiting [MiniMed News](https://news.minimed.com), which will include a comprehensive overview of the company's financial performance through the end of the fiscal year on April 24, 2026.

In addition, MiniMed will host a live webcast at 5:45 a.m. PDT the same day to discuss these results in detail. Interested stakeholders can tune in via [MiniMed Investors](https://investors.minimed.com). For those unable to participate in the live event, a replay and transcript will be made available within 24 hours after the broadcast, accessible through the "Events" link on their investor relations page.

With a steadfast commitment to supporting individuals with diabetes, MiniMed has been at the forefront of insulin delivery and related technologies for over 40 years, improving the quality of life for patients across more than 80 countries. The company’s fully integrated ecosystem of products, which includes insulin delivery systems, continuous glucose monitors (CGMs), and user-friendly app experiences, reinforces its dedication to anticipating patient needs and alleviating daily burdens associated with diabetes management.

As always, forward-looking statements regarding financial results are subject to risks and uncertainties that may cause actual outcomes to differ, as detailed in MiniMed’s periodic SEC filings.

For further updates and information, please visit [MiniMed Press Release](https://www.prnewswire.com/news-releases/minimed-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026-302740889.html).

As MiniMed (Nasdaq: MMED) prepares to announce its financial results for the fourth quarter and full fiscal year 2026 on June 3, market participants should closely monitor several key indicators that could impact the company's future performance.

First, investors should focus on sales growth and new customer acquisition metrics. MiniMed operates in a competitive sector where innovation and usage of advanced technology are crucial. Trends such as adoption rates of continuous glucose monitoring (CGM) systems and insulin delivery devices will be vital. An unexpected increase in sales, particularly from their existing user base, would indicate customer satisfaction and confidence in MiniMed's products.

Additionally, product pipeline updates are essential. The company's ability to launch new technologies or improve existing products can significantly affect its market position. MiniMed has historically focused on developing integrated systems that offer a seamless user experience; any announcements regarding upcoming products or upgrades during the earnings call may provide insight into future revenue streams.

Cost management and operational efficiency are other areas worthy of scrutiny. Investors should analyze the company's expenses in relation to revenue growth. A strong focus on reducing operational costs while expanding margins could signal a healthy and sustainable financial model.

Finally, be aware of guidance for the upcoming quarters. Forward-looking statements from management can provide valuable context about expectations for revenue growth, R&D investments, and challenges posed by the broader economic environment, including supply chain issues or regulatory changes.

In conclusion, while market sentiment towards MiniMed may fluctuate based on quarterly results, a thorough evaluation of customer demand, product development, financial health, and forward guidance will be pivotal in determining the company's trajectory. Investors should be prepared for a range of outcomes and approach market entry with caution until the full context emerges post-announcement.